RAPID MICRO BIOSYSTEMS INC
For the period ended Mar 31, 2024. Filed May 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 3, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Condensed Consolidated Financial Statements (Unaudited)
Notes to condensed consolidated financial statements
(Amounts in thousands, except share and per share amounts)
- Nature of the business and basis of presentation
Rapid Micro Biosystems, Inc. (the “Company”) was incorporated under the laws of the State of Delaware on December 29, 2006. The Company develops, manufactures, markets and sells Growth Direct systems (“Systems”) proprietary consumables, laboratory information management system (“LIMS”) connection software, and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices and personal care products. The Company’s technology uses a highly sensitive camera and the natural auto fluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The Company currently sells to customers in North America, Europe and the Asia-Pacific region. The Company is headquartered in Lowell, Massachusetts.
Basis of presentation
These condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries in Germany and Switzerland. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s audited consolidated financial statements for the year ended December 31, 2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2024 and the results of its operations and its cash flows for the three months ended March 31, 2024 and 2023. The financial data and other information disclosed in these notes related to the three months ended March 31, 2024 and 2023 are also unaudited. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period.
Liquidity
The Company has incurred recurring losses and net cash outflows from operations since its inception. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its existing cash and cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months following the date these unaudited interim condensed consolidated financial statements were issued.
- Summary of significant accounting policies
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, calculating the standalone selling price for revenue recognition, the valuation of inventory, and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific and relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
There have been no significant changes to the Company's significant accounting policies during the three months ended March 31, 2024, as compared to those disclosed in Note 2 of the audited consolidated financial statements as of December 31, 2023 filed with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Risk of concentrations of credit, significant customers and significant suppliers
Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments and accounts receivable. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash and cash equivalents and investments with financial institutions that management believes to be of high credit quality. The Company has not experienced any other-than-temporary losses with respect to its cash equivalents and investments and does not believe that it is subject to unusual credit risk beyond the credit risk associated with commercial banking relationships.
Significant customers are those which represent more than 10% of the Company’s total revenue or accounts receivable balance at each respective balance sheet date. The following table presents customers that represented 10% or more of the Company’s total revenue:
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Customer A | 19.4% | 20.1% |
| Customer B | 14.3% | 27.0% |
| 33.7% | 47.1% | |
The following table presents customers that represented 10% or more of the Company’s accounts receivable:
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Customer B | 41.9% | 16.4% |
| Customer A | 13.5% | 10.7% |
| Customer C | * | 21.4% |
| Customer D | * | 12.4% |
| 55.4% | 60.9% |
*– less than 10%
The Company relies on third parties for the supply and manufacture of certain components of its products as well as third-party logistics providers. There were no significant concentrations around a single third-party supplier, manufacturer, or logistics provider for the three months ended March 31, 2024 or 2023.
Cash and cash equivalents
The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. At both March 31, 2024 and December 31, 2023, the Company held cash of $0.1 million in banks located outside of the United States.
Restricted cash
As of both March 31, 2024 and December 31, 2023, the Company was required to maintain guaranteed investment certificates of $0.3 million with maturities of three months to one year that are subject to an insignificant risk of changes in value. The guaranteed investment certificates are held for the benefit of the landlord in connection with operating leases which have remaining terms of greater than one year and are classified as restricted cash (non-current) on the Company’s consolidated balance sheets.
Software Development Costs
The Company accounts for software development costs for internal-use software under the provisions of ASC 350-40,“Internal-Use Software” (“ASC 350”). Accordingly, certain costs to develop internal-use computer software are capitalized, provided these costs are expected to be recoverable. There was $1.4 million of software development costs related to the Company's enterprise resource planning ("ERP") system capitalized in other long-term assets at both March 31, 2024 and December 31, 2023, net of accumulated amortization of $0.8 million and $0.7 million, respectively. These capitalized costs are being amortized on a straight-line basis over the initial subscription term offive years. For each of the three months ended March 31, 2024 and 2023, there was $0.1 million of amortization expense related to capitalized software development costs recorded in the condensed consolidated statements of operations.
Fair value measurements
Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
The Company’s cash equivalents, short-term and long-term investments are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.
Product warranties
The Company offers aone-year limited assurance warranty on System sales, which is included in the selling price. The accrual for these warranty obligations is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The following table presents a summary of changes in the amount reserved for warranty cost (in thousands):
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Balance, beginning of period | $689 | $872 |
| Warranty provisions | — | — |
| Warranty repairs | — | (346) |
| Balance, end of period | $689 | $526 |
Segment information
The Company determined its operating segment after considering the Company’s organizational structure and the information regularly reviewed and evaluated by the Company’s chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company has determined that its CODM is its Chief Executive Officer. The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. On the basis of these factors, the Company determined that it operates and manages its business asone operating segment, that develops, manufactures, markets and sells Systems and related LIMS connection software, consumables and services; and accordingly hasone reportable segment for financial reporting purposes. Substantially all of the Company’s long-lived assets are held in the United States.
Revenue recognition
Remaining performance obligations
The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and(iii)variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. The Company does not have material remaining performance obligations associated with contracts with terms greater than one year.
Contract balances from contracts with customers
Contract assets arise from customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company’s right to payment is conditional and not only subject to the passage of time. The Company had $0.1 million in contract assets as of both March 31, 2024 and December 31, 2023, included in prepaid expenses and other current assets.
Contract liabilities represent the Company’s obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. The Company has a contract liability related to service revenue, which consists of amounts that have been invoiced but that have not been recognized as revenue. Amounts expected to be recognized as revenue within 12 months of the balance sheet date are classified as current deferred revenue and amounts expected to be recognized as revenue beyond 12 months of the balance sheet date are classified as non-current deferred revenue. The Company didnot record any non-current deferred revenue as of March 31, 2024 or December 31, 2023. Deferred revenue was $6.2 million and $6.0 million at March 31, 2024 and December 31, 2023, respectively. Revenue recognized during the three months ended March 31, 2024 and 2023 that was included in deferred revenue at the prior period-end was $1.4 million and $1.0 million, respectively.
Disaggregated revenue
The Company disaggregates revenue based on the recurring and non-recurring nature of the underlying sale. Recurring revenue includes sales of consumables and service contracts. The Company considers these to be recurring revenues because customers typically place purchase orders on a periodic basis as they use their Growth Direct system(s) over time. These arrangements typically contain a single performance obligation and thus the entire consideration to which the Company is entitled is allocated entirely to that performance obligation. Non-recurring revenue includes sales of systems, LIMS connection software, validation services, and field services, and typically contains multiple performance obligations. The Company considers these to be non-recurring revenues because customers typically place single purchase orders for a bundle of products and services on a one-time or infrequent basis. For these arrangements, significant judgment is applied in identifying the distinct performance obligations, determination of the transaction price, transaction price allocation, and determination of standalone selling price for each of the distinct performance obligations.
The following table presents the Company’s revenue by the recurring or non-recurring nature of the revenue stream (in thousands):
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Product and service revenue — recurring | $3,743 | $3,253 |
| Product and service revenue — non-recurring | 1,868 | 1,782 |
| Total revenue | $5,611 | $5,035 |
The following table presents the Company’s revenue by customer geography (in thousands):
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| United States | $2,149 | $1,703 |
| Switzerland | 972 | 973 |
| Japan | 800 | 1,386 |
| Germany | 464 | 413 |
| All other countries | 1,226 | 560 |
| Total revenue | $5,611 | $5,035 |
Advertising costs
Advertising costs are expensed as incurred and are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising costs were less than $0.1 million during each of the three months ended March 31, 2024 and 2023.
Stock-based compensation
The Company measures all stock-based awards granted to employees, officers and directors based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with (i) service-based vesting conditions only and (ii) stock-based awards with both service-based and Company performance vesting conditions, and records the expense for these awards using the straight-line method. Forfeitures are accounted for prospectively as they occur.
The Company measures all restricted stock units granted to employees based on the common stock value on the date of grant. The purchase price of the restricted stock is the common stock value on the date of grant.
Recently issued accounting pronouncements
The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups ("JOBS") Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the newer revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic companies.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. The new standard requires enhanced disclosures about a public entity's reportable segments including more detailed information about a reportable segment's expenses. The amendments in this update apply to all public entities that are required to report segment information, and include those entities that have a single reportable segment. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this update are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.
- Fair value of financial assets and liabilities
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands):
| Fair value measurements as of March 31, 2024 | ||||
|---|---|---|---|---|
| Level 1 | Level 2 | Level 3 | Total | |
| Assets | ||||
| Cash equivalents | $19,346 | $— | $— | $19,346 |
| Short-term investments | 52,923 | 4,180 | — | 57,103 |
| $72,269 | $4,180 | $— | $76,449 | |
| Fair value measurements as of December 31, 2023 | ||||
|---|---|---|---|---|
| Level 1 | Level 2 | Level 3 | Total | |
| Assets | ||||
| Cash equivalents | $20,306 | $— | $— | $20,306 |
| Short-term investments | 62,625 | 5,143 | — | 67,768 |
| Long-term investments | 2,911 | — | — | 2,911 |
| $85,842 | $5,143 | $— | $90,985 | |
During the three months ended March 31, 2024 and 2023, there were no transfers in or out of Level 3.
Valuation of short-term and long-term investments
U.S. Treasury bills and notes included in short-term and long-term investments were valued by the Company using quoted prices in active markets for identical securities, which represents a Level 1 measurement within the fair value hierarchy. The Company's certificates of deposit included in short-term and long-term investments were valued using quoted prices for similar assets in active markets (or identical assets in inactive markets), which represent a Level 2 measurement within the fair value hierarchy.
- Investments
Short-term and long-term investments by investment type consisted of the following (in thousands):
| March 31, 2024 | ||||
|---|---|---|---|---|
| Amortizedcost | Grossunrealizedgains | Grossunrealizedlosses | Fairvalue | |
| Short-term investments | ||||
| Certificates of Deposit | $4,192 | $— | $(11) | $4,181 |
| U.S. Government Treasury Bills | 14,795 | — | (6) | 14,789 |
| U.S. Government Treasury Notes | 38,194 | 3 | (64) | 38,133 |
| $57,181 | $3 | $(81) | $57,103 | |
| December 31, 2023 | ||||
|---|---|---|---|---|
| Amortizedcost | Grossunrealizedgains | Grossunrealizedlosses | Fairvalue | |
| Short-term investments | ||||
| Certificates of Deposit | $5,164 | $— | $(21) | $5,143 |
| U.S. Government Treasury Bills | 16,184 | 9 | — | 16,193 |
| U.S. Government Treasury Notes | 46,536 | 42 | (146) | 46,432 |
| $67,884 | $51 | $(167) | $67,768 | |
| Long-term Investments | ||||
| U.S. Government Treasury Notes - Maturity Up To Two Years | 2,896 | 15 | — | 2,911 |
| $2,896 | $15 | $— | $2,911 | |
- Inventory
Inventory consisted of the following (in thousands):
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Raw materials | $11,654 | $12,873 |
| Work in process | 423 | 150 |
| Finished goods | 8,341 | 6,938 |
| Total | $20,418 | $19,961 |
Raw materials, work in process and finished goods were net of adjustments to net realizable value of $0.7 million and $0.6 million as of March 31, 2024 and December 31, 2023, respectively.
- Prepaid expenses and other current assets
Prepaid expenses and other current assets consisted of the following (in thousands):
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Prepaid insurance | $803 | $1,282 |
| Contract asset | 94 | 51 |
| Deposits | 742 | 667 |
| Other receivables | 333 | 137 |
| Prepaid financing fees | 295 | 292 |
| Other | 1,018 | 440 |
| $3,285 | $2,869 |
- Property and equipment, net
Property and equipment, net consisted of the following (in thousands):
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Manufacturing and laboratory equipment | $13,850 | $13,750 |
| Computer hardware and software | 2,034 | 1,960 |
| Office furniture and fixtures | 589 | 589 |
| Leasehold improvements | 8,995 | 8,551 |
| Construction-in-process | 2,165 | 2,292 |
| 27,633 | 27,142 | |
| Less: Accumulated depreciation | (15,018) | (14,310) |
| $12,615 | $12,832 |
Depreciation and amortization expense related to property and equipment was $0.7 million for each of the three months ended March 31, 2024 and 2023.
- Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Accrued employee compensation and benefits expense | $2,779 | $4,808 |
| Accrued vendor expenses | 3,198 | 4,017 |
| Accrued warranty expense | 689 | 689 |
| Accrued taxes | 259 | 252 |
| Other | 124 | 141 |
| $7,049 | $9,907 |
- Common stock and common stock warrants
As of both March 31, 2024 and December 31, 2023, the Company’s restated certificate of incorporation authorized the issuance of Class A and Class B common stock. Each share of Class A common stock entitles the holder toone vote on all matters submitted to a vote of the Company’s stockholders. The Company’s Class B common stock is non-voting. Class A and Class B common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of Preferred Stock. As of March 31, 2024, no cash dividends had been declared or paid.
As of March 31, 2024, the Company had reserved 24,147,346 shares of Class A common stock for the exercise of outstanding stock options and warrants, vesting of restricted stock units, the number of shares remaining available for grant under the Company’s 2021 Incentive Award Plan (see Note 10), the number of shares available for purchase under the Company’s Employee Stock Purchase Plan (see Note 10) and the conversion of Class B common stock.
As of both March 31, 2024 and December 31, 2023, outstanding warrants to purchase common stock consisted of the following:
| Issuance date | Contractual term | Balance sheetclassification | Shares of common stock issuable uponexercise of warrant | Weighted average exercise price |
|---|---|---|---|---|
| (in years) | ||||
| July 24, 2017 | 10 | Equity | 17,194 | $292.81 |
| April 12, 2018 | 10 | Equity | 30,000 | $1.00 |
| July 14, 2021 * | 10 | Equity | 975,109 | $1.46 |
*– In connection with the IPO, preferred stock warrants were automatically converted to Class A common stock warrants. The contractual term of the converted Class A common stock warrants remained consistent with the original term of the preferred stock warrants, with original issue dates between 2017-2020.
- Stock-based compensation
2010 Stock Option and Grant Plan
The Company’s 2010 Stock Option and Grant Plan (the “2010 Plan”) provided for the Company to grant incentive stock options or nonqualified stock options, restricted stock awards and other stock-based awards to employees, officers, directors and consultants of the Company.
Following the effectiveness of the Company's initial public offering ("IPO") in July 2021, no additional awards are being granted under the 2010 Plan and shares of existing outstanding options that were issued under the 2010 Plan and are forfeited or canceled will be available for grant under the 2021 Incentive Award Plan.
2021 Incentive Award Plan
In July 2021, the board of directors adopted, and the Company’s stockholders approved, the 2021 Incentive Award Plan (the “2021 Plan”). The 2021 Plan provides for the grant of stock options, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based and cash-based awards. The 2021 Plan has a term often years. The aggregate number of shares of Class A common stock available for issuance under the 2021 Plan is equal to the sum of (i)4,200,000 shares; (ii) any shares which are subject to the 2010 Plan awards that become available for issuance under the 2021 Plan; and (iii) an annual increase forten years on the first day of each calendar year beginning on January 1, 2022, equal to the lesser of (A)5% of the aggregate number of shares of Class A common stock outstanding on the last day of the immediately preceding calendar year and (B) such smaller amount of shares as determined by the board of directors. No more than 33,900,000 shares of Class A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. As of March 31, 2024, there were 4,738,976 shares available for issuance under the 2021 Plan.
The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees and directors:
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Risk-free interest rate | 4.1% | 4.2% |
| Expected term (in years) | 6.0 | 6.0 |
| Expected volatility | 49.5% | 47.8% |
| Expected dividend yield | 0% | 0% |
Stock options
The following table summarizes the Company’s stock option activity since December 31, 2023:
| Number of shares | Weighted average exercise price | Weighted average remaining contractual term | Aggregate intrinsic value | |
|---|---|---|---|---|
| (in years) · (in thousands) | ||||
| Outstanding as of December 31, 2023 | 6,530,511 | $2.59 | 7.12 | $— |
| Granted | 751,920 | 0.95 | ||
| Exercised | (20) | 0.75 | ||
| Expired | (139,529) | 8.08 | ||
| Forfeited | (31,707) | 1.28 | ||
| Outstanding as of March 31, 2024 | 7,111,175 | $2.31 | 7.28 | $263 |
| Options vested and expected to vest as of March 31, 2024 | 7,111,175 | $2.31 | 7.28 | $263 |
| Options exercisable as of March 31, 2024 | 4,003,111 | $2.60 | 6.09 | $180 |
The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s Class A common stock for those options that had exercise prices lower than such fair value.
The intrinsic value of stock options exercised during each of the three months ended March 31, 2024 and 2023 was less than $0.1 million.
The weighted average grant-date fair value per share of stock options granted during the three months ended March 31, 2024 and 2023 was $0.50 and $0.63, respectively.
Restricted stock units
Restricted stock unit grants to employees typically have athree-year service-based vesting term in which vesting occurs annually on the anniversary of the grant date. During the three months ended March 31, 2024, the Company granted restricted stock units with service-based vesting conditions only. The Company expenses the fair value of the restricted stock units over the expected vesting period and accounts for forfeitures prospectively as they occur.
The following table summarizes the Company's restricted stock units activity since December 31, 2023:
| Number of shares | Weighted average fair value | |
|---|---|---|
| Unvested as of December 31, 2023 | 1,681,760 | $2.28 |
| Granted | 420,640 | $0.95 |
| Vested | (263,175) | $4.39 |
| Forfeited | (16,341) | $2.80 |
| Unvested as of March 31, 2024 | 1,822,884 | $1.66 |
The weighted average grant-date fair value per share of restricted stock units granted during the three months ended March 31, 2024 and 2023 was $0.95 and $1.20, respectively.
2021 Employee Stock Purchase Plan
In July 2021, the board of directors adopted, and the Company’s stockholders approved, the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which became effective in connection with the IPO of Class A common stock. The aggregate number of shares of Class A common stock available for issuance under the 2021 ESPP is equal to (i)400,000 shares and (ii) an annual increase forten years on the first day of each calendar year beginning on January 1, 2022, equal to the lesser of (A)1% of the aggregate number of shares of Class A common stock outstanding on the last day of the immediately preceding calendar year and (B) such smaller amount of shares as determined by the board of directors. No more than 6,300,000 shares of Class A common stock may be issued under the 2021 ESPP.
Under the 2021 ESPP, eligible employees may purchase shares of the Company’s common stock through payroll deductions of up to 15% of eligible compensation during an offering period. Generally, each offering period will be for 6 months as determined by the Company's board of directors. In no event may an employee purchase more than 100,000 shares per offering period based on the closing price on the first trading date of an offering period or the last trading date of an offering period, or more than $25,000 worth of stock during any calendar year. The purchase price for shares to be purchased under the 2021 ESPP is 85% of the lesser of the market price of the Company's common stock on the first trading date of an offering period or on any purchase date during an offering period (March 14 or September 14).
During the three months ended March 31, 2024, there were 198,299 shares of Class A common stock purchased under the 2021 ESPP. The Company recognized less than $0.1 million of expense related to the 2021 ESPP for each of the three months ended March 31, 2024 and 2023. As of March 31, 2024,1,045,858 shares were available for future issuance under the 2021 ESPP.
The Company estimates the fair value of shares issued to employees under the 2021 ESPP using the Black-Scholes option-pricing model. The following weighted average assumptions were used in the calculation of fair value of shares under the 2021 ESPP at the grant date for the three months ended March 31, 2024 and 2023:
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Risk-free interest rate | 5.4% | 4.7% |
| Expected term (in years) | 0.5 | 0.5 |
| Expected volatility | 49.4% | 47.8% |
| Expected dividend yield | 0% | 0% |
2023 Inducement Plan
In May 2023, the board of directors adopted the 2023 Inducement Plan (the “Inducement Plan”) pursuant to which the Company reserved 330,000 shares of Class A common stock to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Company as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan provides for the grant of equity-based awards in the form of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and dividend equivalent rights. The Inducement Plan was adopted by the board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
In May 2023, pursuant to the Inducement Plan, the Company granted inducement awards to the Company's Senior Vice President, Sales & Marketing, in the form of an option to purchase 220,000 shares of the Company's Class A common stock, with an exercise price per share of $0.83, and 110,000 restricted stock units. The option and restricted stock unit awards were granted as inducements material to the commencement of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
In February 2024, the Company amended its Inducement Plan to reserve an additional 225,000 shares of its Class A common stock. The amendment was adopted by the compensation committee of the board of directors, without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
In March 2024, pursuant to the Inducement Plan as amended, the Company granted inducement awards to the Company's Vice President, Legal, in the form of an option to purchase 150,000 shares of the Company's Class A common stock, with an exercise price per share of $0.99, and 75,000 restricted stock units. The option and restricted stock unit awards were granted as inducements material to the commencement of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
As of March 31, 2024, no shares were available for future issuance under the Inducement Plan.
Stock-based compensation
Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands):
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cost of revenue | $147 | $174 |
| Research and development | 129 | 157 |
| Sales and marketing | 105 | 131 |
| General and administrative | 704 | 781 |
| Total stock-based compensation expense | $1,085 | $1,243 |
As of March 31, 2024, total unrecognized compensation expense related to unvested stock options held by employees and directors was $3.8 million, which is expected to be recognized over a weighted average period of 1.8 years. Additionally, unrecognized compensation expense related to unvested restricted stock units held by employees and directors was $2.4 million, which is expected to be recognized over a weighted average period of 1.9 years.
- Income taxes
During the three months ended March 31, 2024 and 2023, the pretax losses incurred by the Company, as well as the research and development tax credits generated, received no corresponding tax benefit because the Company concluded that it is more likely than not that the Company will be unable to realize the value of any resulting deferred tax assets. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance in the future.
The Company’s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate, adjusted for the effect of discrete items arising in that quarter. The income tax provision was generated from operations in Germany and Switzerland.
The impact of such discrete items could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings or losses versus annual projections. In each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, a cumulative adjustment is made in that quarter.
The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, as of March 31, 2024 and December 31, 2023 the Company has recorded a full valuation allowance against its net deferred tax assets.
The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by U.S. federal, state and international jurisdictions, where applicable. There are currently no pending tax examinations in the U.S., and the Company has not received notice of examination from any jurisdictions in the U.S.
- Net loss per share
As of March 31, 2024, the Company had Class A common stock and Class B common stock. Both classes have the same rights to the Company’s earnings and neither of the shares have any prior or senior rights to dividends to other shares.
Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Numerator: | ||
| Net loss | $(13,322) | $(13,887) |
| Denominator: | ||
| Weighted average Class A common shares outstanding—basic and diluted | 37,936,306 | 37,259,201 |
| Weighted average Class B common shares outstanding—basic and diluted | 5,309,529 | 5,553,379 |
| Total shares for EPS—basic and diluted | 43,245,835 | 42,812,580 |
| Net loss per share attributable to Class A common stockholders—basic and diluted | $(0.31) | $(0.32) |
| Net loss per share attributable to Class B common stockholders—basic and diluted | $(0.31) | $(0.32) |
The Company’s potentially dilutive securities, which include stock options, restricted stock, restricted stock units, and common stock warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
| March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Options to purchase common stock | 7,111,175 | 6,064,365 |
| Unvested restricted common stock | 1,822,884 | 286,324 |
| Warrants to purchase common stock | 286,324 | 874,714 |
| Options to purchase common stock under ESPP | 11,559 | 5,244 |
| 9,231,942 | 7,230,647 | |
- Leases
The Company determines if an arrangement is or contains a lease at inception, which is the date on which the terms of the contract are agreed to, and the agreement creates enforceable rights and obligations. Under ASC 842, a contract is or contains a lease when (i) explicitly or implicitly identified assets have been deployed in the contract and (ii) the customer obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company also considers whether its service arrangements include the right to control the use of an asset. See Note 2 for more information on the Company’s accounting policies for leases.
The Company leases office and manufacturing space under operating lease agreements that have initial terms ranging from approximately 8 to 10 years. The Company leases furniture under a financing lease agreement that has an initial term of approximately 8 years. Some leases includeone or more options to renew, generally at the Company's sole discretion, with renewal terms that can extend the lease term by up to 5 years. In addition, certain leases contain termination options, where the rights to terminate are held by either the Company, the lessor, or both parties. Options to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise the option. Options to terminate a lease are excluded from the lease term when it is reasonably certain that the Company will not exercise the option. The Company’s leases generally do not contain any material restrictive covenants or residual value guarantees.
Supplemental cash flow information related to leases is as follows (in thousands):
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash paid for amounts included in measurement of lease liabilities: | ||
| Operating cash outflows - payments on operating leases | $331 | $316 |
| Operating cash outflows - payments on financing leases | $9 | $10 |
| Financing cash outflows - payments on financing leases | $10 | $9 |
Supplemental balance sheet information related to the Company’s operating and financing leases is as follows (in thousands):
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Operating Leases: | ||
| Operating lease assets | $5,732 | $5,972 |
| Operating lease liabilities, short-term | $1,109 | $1,090 |
| Operating lease liabilities, long-term | 5,665 | 5,952 |
| Total operating lease liabilities | $6,774 | $7,042 |
| Financing Leases: | ||
| Office furniture and fixtures | $386 | $386 |
| Accumulated depreciation | (130) | (118) |
| Net property, plant and equipment | $256 | $268 |
| Lease liabilities, short-term | $43 | $42 |
| Lease liabilities, long-term | 252 | 262 |
| Total financing lease liabilities | $295 | $304 |
| Weighted-average remaining lease term - operating leases (in years): | 5.29 | 5.54 |
| Weighted-average remaining lease term - financing leases (in years): | 5.25 | 5.50 |
| Weighted-average discount rate - operating leases: | 3.8% | 3.8% |
| Weighted-average discount rate - financing leases: | 12.0% | 12.0% |
The components of lease expense were as follows (in thousands):
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating lease cost | $305 | $297 |
| Financing lease cost - amortization of right-of-use asset | 12 | 12 |
| Financing lease cost - interest on lease liability | 9 | 10 |
| Variable lease cost | 205 | 170 |
| Total lease cost | $531 | $489 |
Operating lease cost is recognized on a straight-line basis over the lease term. Total rent expense, including the Company’s share of the lessors’ operating expenses, was $0.5 million for each of the three months ended March 31, 2024 and 2023. Financing lease cost includes asset amortization on a straight-line basis over the lease term and interest accretion calculated using the effective interest method. Total financing lease asset depreciation and interest expense was less than $0.1 million for each of the three months ended March 31, 2024 and 2023.
Maturities of the Company’s operating lease liabilities as of March 31, 2024 were as follows (in thousands):
| Operating Lease Maturities | |
|---|---|
| 2024 (excluding the three months ended March 31) | $1,003 |
| 2025 | 1,368 |
| 2026 | 1,401 |
| 2027 | 1,435 |
| 2028 | 1,468 |
| Thereafter | 805 |
| Total lease payments | $7,480 |
| Less imputed interest | (706) |
| Total present value of lease liabilities | $6,774 |
Maturities of the Company’s financing lease liability as of March 31, 2024 were as follows (in thousands):
| Financing Lease Maturities | |
|---|---|
| 2024 (excluding the three months ended March 31) | $56 |
| 2025 | 75 |
| 2026 | 75 |
| 2027 | 75 |
| 2028 | 75 |
| Thereafter | 38 |
| Total lease payments | $394 |
| Less imputed interest | (99) |
| Total present value of lease liabilities | $295 |
- Commitments and contingencies
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to customers, vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and certain of its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March 31, 2024 and December 31, 2023.
Legal proceedings
The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to legal proceedings.
- Benefit plans
The Company maintains a defined contribution savings plan under Section 401(k) of the Code. This plan covers all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the plan may be made at the discretion of the Company’s board of directors. The Company made contributions of $0.3 million and $0.2 million to the plan during the three months ended March 31, 2024 and 2023, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.